Evidence map›Paper›PMID 36709460›Full record

ArticleMolecular biotechnology2024

In Silico Design and Experimental Validation of Novel Oxazole Derivatives Against Varicella zoster virus.

Vasyl Kovalishyn, Oleksandr Severin, Maryna Kachaeva, Oleksandr Kobzar, Kathy A Keith, Emma A Harden, Caroll B Hartline, Scott H James, Andriy Vovk, Volodymyr Brovarets

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Vasyl KovalishynV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the National Academy of Science of Ukraine, Kyiv, 02094, Ukraine. vkovalishyn@gmail.com.ORCID http://orcid.org/0000-0002-9352-7332
Oleksandr SeverinV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the National Academy of Science of Ukraine, Kyiv, 02094, Ukraine.
Maryna KachaevaV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the National Academy of Science of Ukraine, Kyiv, 02094, Ukraine.
Oleksandr KobzarV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the National Academy of Science of Ukraine, Kyiv, 02094, Ukraine.
Kathy A KeithDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA.
Emma A HardenDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA.
Caroll B HartlineDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA.
Scott H JamesDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA.
Andriy VovkV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the National Academy of Science of Ukraine, Kyiv, 02094, Ukraine.
Volodymyr BrovaretsV.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the National Academy of Science of Ukraine, Kyiv, 02094, Ukraine.
Institute of Bioorganic Chemistry and Petrochemistry V.P. Kukhar · UAUniversity of Alabama at Birmingham · US

Funding

National Institute of Allergy and Infectious Diseases (US) HHSN75N93019D00016National Research Foundation of Ukraine 2020.01/0075
6 · The paper itself

Abstract

Varicella zoster virus (VZV) infection causes severe disease such as chickenpox, shingles, and postherpetic neuralgia, often leading to disability. Reactivation of latent VZV is associated with a decrease in specific cellular immunity in the elderly and in patients with immunodeficiency. However, due to the limited efficacy of existing therapy and the emergence of antiviral resistance, it has become necessary to develop new and effective antiviral drugs for the treatment of diseases caused by VZV, particularly in the setting of opportunistic infections. The goal of this work is to identify potent oxazole derivatives as anti-VZV agents by machine learning, followed by their synthesis and experimental validation. Predictive QSAR models were developed using the Online Chemical Modeling Environment (OCHEM). Data on compounds exhibiting antiviral activity were collected from the ChEMBL and uploaded in the OCHEM database. The predictive ability of the models was tested by cross-validation, giving coefficient of determination q

Indexed as

Antiviral AgentsHerpesvirus 3, HumanOxazolesQuantitative Structure-Activity RelationshipComputer SimulationDrug DesignHumansMachine LearningAntiviral AgentsOxazolesAntiviral activityDockingIn Silico designOn-line Chemical Database and Modeling EnvironmentOxazole derivativesVaricella zoster virus

Identifiers

PMID36709460
OpenAlexW4318428512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.